Table 2.

Prognostic value of basal type breast cancer delineated by two different immunopanels.

Subgroup	Hazard ratio (95%CI)	p value	5-year survival rate (95%CI) (%)	p value (log-rank)
All patients (n = 179)
'CK5/6 or 14 or 17'	1.46 (0.90–2.37)	0.127		0.124
Positive			63.5 (50.7–73.8)
Negative			75.3 (66.1–82.4)
Vimentin	1.22 (0.69–2.14)	0.497		0.496
Positive			59.5 (42.1–73.3)
Negative			73.9 (65.7–80.4)
'Vimentin or CK5/6 or	1.73 (1.07–2.81)	0.026		0.024
14 or 17'
Positive			61.5 (49.3–71.6)
Negative			77.6 (68.2–84.5)
Triple negative patients (n = 54)
'CK5/6 or 14 or 17'	0.50 (0.21–1.20)	0.122		0.115
Positive			71.8 (54.9–83.3)
Negative			52.5 (25.2–74.0)
Vimentin	0.64 (0.28–1.48)	0.297		0.293
Positive			69.0 (48.8–82.5)
Negative			68.0 (46.1–82.5)
'Vimentin or CK5/6 or	0.56 (0.22–1.45)	0.234		0.227
14 or 17'
Positive			78.6 (62.9–88.2)
Negative			58.3 (27.0–80.1)
Non-triple negative patients (n = 125)
'CK5/6 or 14 or 17'	2.61 (1.40–4.84)	0.002		0.002
Positive			50.9 (30.7–67.9)
Negative			77.8 (67.9–84.9)
Vimentin*	3.26 (1.37–7.77)	0.008		0.005
Positive			25.4 (3.8–56.4)
Negative			75.2 (66.1–82.2)
'Vimentin or CK5/6 or	3.04 (1.66–5.56)	<0.001		<0.001
14 or 17'
Positive			47.5 (29.1–63.8)
Negative			80.1 (70.2–87.0)

*In a non-triple negative group only 9 patients were positive for vimentin. Thus, results of survival analysis should be regarded as being inconclusive and they are showed for comparative purposes only.